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Abstract
Acquired aplastic anemia (AA) is the typical
bone marrow failure syndrome characterized
by an empty bone marrow; an immune-medi-
ated pathophysiology has been demonstrated
by experimental works as well as by clinical ob-
servations. Immunusuppressive therapy (IST)
is a key treatment strategy for aplastic anemia;
since 20 years the standard IST for AA patients
has been anti-thymocyte globuline (ATG) plus
cyclosporine  A  (CyA),  which  results  in  re-
sponse rates ranging between 50% and 70%,
and even higher overall survival. However, pri-
mary and secondary failures after IST remain
frequent, and to date all attempts aiming to
overcome this problem have been unfruitful.
Here we review the state of the art of IST for
AA in 2010, focusing on possible strategies to
improve current treatments. We also discuss
very recent data which question the equality of
different ATG preparations, leading to a pos-
sible reconsideration of the current standards
of care for AA patients.
Introduction
Aplastic anemia (AA) is the most typical
example of bone marrow failure, character-
ized  by  an  empty  or  fatty  bone  marrow
leading to the subsequent pancytopenia.1 Re-
cently  it  has  been  reported  that  in  some
adults AA may be due to inherited abnormal-
ities.2 However, idiopathic AA is usually con-
sidered  an  immune-mediated  disease.3 Ac-
cording to the most accepted view, self-reac-
tive T cells cause a damage of the hematopoi-
etic  stem  cells  (and  possibly  of  committed
progenitors)  through  a  cell-cell  interaction
(via Fas/Fas-L, granzyme, perforine)4 and the
production  of  inhibitory  cytokines  such  as
IFN-γ, TNF-α and TGF-β.5-7 The role of T cells
was confirmed by the identification, in vivo,
of oligoclonal T cells,8-10 and by the demon-
stration  of  their  pathogenic  role  either  in
vitro or in vivo.10,11 All these findings make
the immune system the therapeutic target in
AA  patients;  immunosuppressive  (IS)  regi-
mens have been largely developed in the past
years, exploiting agents that affect distinct
steps of the immune response.
Immunosuppression 
for aplastic anemia
The standard immunosuppression: anti-
thymocyte globuline plus cyclosporine A
Initial observations showed that some AA pa-
tients failing donor engraftment following allo-
geneic stem cell transplantation rescued autolo-
gous hematopoiesis12 and that in other patients
treatment with anti-lymphocyte globuline (ALG)
resulted beneficial.13,14 In fact, the efficacy of
immunosuppressive  treatment  (IST)  by  ALG
was  confirmed  in  a  prospective,  placebo-con-
trolled, randomized trial, in 1983.15 In order to
improve the response rate and reduce the risk
of subsequent relapse, several immunosuppres-
sive agents have been associated to anti-thymo-
cyte globuline (ATG) or ALG (such as corticos-
teroids,16 androgens)17,18 but  cyclosporine  A
(CyA) only resulted in an increased response
rate,19 with an improved long-term failure-free
survival.20 Since the early ‘90s, ATG + CyA was
considered  the  standard  IST  for  AA  patients,
with an expected 50-60% probability of response
and 60% overall survival at one year.21-23
The most recent studies have shown im-
proved overall survival (above 80% at 1 year),
regardless of the initial response to IST,24-26
likely due to a better supportive care and sal-
vage treatment (mainly SCT). However, treat-
ment-failure remains a major problem after
first-line IST. In fact, about one third of AA pa-
tients do not respond to their initial IST; in
addition, within responders patients, half of
them require long-term IS maintenance treat-
ment by CyA to sustain the response. In fact,
recent studies showed that CyA-dependency
ranges between 25 and 50% of patients and
the patients who require long-term CyA treat-
ment  present  the  higher  risk  to  relapse
(about  30-50%  of  responders).22-24 Further-
more, the development of clinical paroxysmal
nocturnal  hemoglobinuria  is  seen  in  about
10% of AA patients after IST;27 clonal evolu-
tion to myelodysplastic syndromes (MDS) or
acute  leukemias  (AML)  accounts  for  about
10-15% of treatment-failures,24,28 and solid tu-
mors account for an additional 10%.29 Thus, a
substantial fraction of AA patients cannot be
considered cured by IST, and understanding
the underlying causes is necessary to develop
salvage strategies.30 While secondary failures
suggest a flare-up of the underlying immune
process,  the  causes  accounting  for  primary
failures (which occur in one third of patients)
may include: i) non-immune pathophysiology
(e.g.,  due  to  misdiagnosis  of  hypoplastic
MDS, or to inherited forms associated to mu-
tation in telomerase complex genes);31 ii) an
insufficient delivered IS (in fact, some refrac-
tory patients may respond to further IST);32-34
iii) a third explanation is the exhaustion of
the  hematopoietic  stem  cells,  which  would
hamper  any  hematological  recovery  regard-
less the control of the pathogenic immune-at-
tack. This latter hypothesis seems supported
by  the  recent  data  showing  that  baseline
telomere  length  is  the  most  powerful  pre-
dictor of long-term survival in AA patients re-
ceiving IST.35 In fact, shorter telomeres were
associated  with  increased  relapse  rate  and
clonal  evolution  (including  monosomy  7),
suggesting that they are a reliable marker for
functional  hematopoietic  stem  cell  damage
(possibly  linked  to  the  replicative  stress  of
residual cells). If confirmed, these data will
provide an informative tool to identify AA pa-
tients who may benefit from an early trans-
plant strategy rather than IST.
Improving standard ATG-based 
immunosuppression: additional or
alternative IS agents
To  improve  the  results  obtained  with  the
standard ATG + CyA, several investigators tried
to deliver an intensified IS by adding a third IS
agent, possibly with a distinct (hopefully syn-
ergistic) mechanism of action. However, this
strategy did not result in a substantial benefit.
The purine synthesis inhibitor mycophenolate
mofetil  (MMF)  was  tested  in  a  prospective
study conducted at NIH, but did not result in ei-
ther increased response (62% at 6 months) or
decreased relapse (37%, despite maintenance
therapy with MMF) in comparison to historical
data.36 The  mammalian  target  of  rapamycin
(mTOR) inhibitor rapamycin/sirolimus (RAPA)37
was  also  tested  in  a  randomized  trial  con-
ducted  at  NIH;  the  addition  of  RAPA  to  the
standard ATG + CyA resulted in a response rate
of 51%, which was comparable to that of the
control arm (ATG + CyA, 62%), with similar re-
lapse and survival rates.38
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Some  investigators  developed  different
strategies of IST, with the aim of retaining (or
possibly increasing) a marked IS activity, ide-
ally with a better toxicity profile. They used
lymphocyte depleting agents other than ATG,
such  as  cyclophosphamide  (CTX)  or  alem-
tuzumab.  High-dose  CTX  (50  mg/kg  intra-
venously on 4 consecutive days) was mainly
tested  at  the  Johns  Hopkins  University;  the
initial results were excellent, with a response
rate of about 70% (even if the time-to-response
appeared  delayed  in  comparison  to  that  ex-
pected with ATG).39 This single-center experi-
ence  continues  to  show  interesting  results,
with the most recent follow up reporting 44
naïve  AA  patients  showing  response  rate,
overall survival and event free survival of 88%,
71% (the majority complete) and 58%, respec-
tively.40 However,  most  investigators  do  not
consider CTX as a feasible treatment option for
AA patients, based on the results of the ran-
domized study versus ATG + CyA conducted at
NIH. This study was early stopped due to in-
creased fatal infectious complications in the
experimental arm (CTX + CyA), related to the
prolonged  neutropenia  resulting  from  CTX
myelotoxicity;41in addition, the latest follow up
did  not  confirm  Johns  Hopkins’  data  sug-
gesting  that  CTX  may  reduce  the  risk  of
MDS/AML development.42
Another candidate agent for inducing lym-
phocyte depletion in AA patients is the anti-
CD52  monoclonal  antibody  alemtuzumab,
which specifically kills CD52-bearing cells via
both  antibody-dependent  cellular  cytotoxicity
and complement-mediated lysis. We have re-
cently  reported,  in  collaboration  with  the
EBMT  Working  Party  for  Severe  Aplastic
Anemia (WPSAA), that an alemtuzumab-based
IS regimen (also including low-dose CyA) was
feasible, safe and effective for the treatment of
AA patients.43 Alemtuzumab was given subcu-
taneously with negligible injection-related side
effects, and the low rate of infectious compli-
cations ruled out most safety concerns; prelim-
inary efficacy data suggested response rates
not  below  standard  IS  regimen  (58%),  with
easy  re-treatment  in  case  of  relapse.  These
data  confirms  observations  from  smaller  se-
ries.44,45 However, recent data from NIH seem
only partially confirm these positive results;46
in  fact,  alemtuzumab  resulted  in  a  56%  re-
sponse rate in relapsed AA (n=23) and 36% in
refractory AA (n=25). However, quite surpris-
ingly, as front line treatment alemtuzumab re-
sulted in a response rate as low as 19% (on 16
patients only); it has to be remarked that in the
NIH  experience  alemtuzumab  was  used  as
single agent, without CyA.
Other IS agents may be also hypothesized
for the treatment of AA; in the past years, the
anti-CD25  monoclonal  antibody  daclizumab
was used for moderate forms of AA, with a re-
sponse rate of about 40%.47,48 Given the proven
role of cytokines in suppressing the hemato  -
poiesis in AA,7 some cytokine inhibitors have
been hypothesized for the treatment of AA, es-
pecially the already available TNF-α inhibitors
etanercept  (a  TNF-receptor/Ig  fusion  pro-
tein),49 infliximab  (a  chimeric  anti-TNF-α
mAb)  and  adalimumab  (a  fully  humanized
anti-TNF-α mAb). One could also hypothesize
that in the future additional IS agents will be
investigated in AA, such as alefacept,50 efal-
izumab,51 anti-IFN agents52 or even immuno  -
modulation by mesenchymal stem cells.53
Current immunosuppression: 
the matter of different ATG 
preparations
ATG is a heterologous anti-serum obtained
by injecting human lymphocytes in animals;
various ATG preparations exist, which differ in
stimulating antigens (peripheral lymphocytes,
thymocytes or even T cell lines), and/or in the
host  animal  (either  horse  or  rabbit).  Thus,
even  if  comprehensive  descriptions  of  the
composition  of  each  anti-serum  are  limited,
they are obviously different;54-56 in addition, at
least in the past, inter-lot variation due to man-
ufacturing  processes  cannot  be  excluded.57
The  majority  of  available  data  coming  from
large randomized clinical trials refer to poly-
clonal ATGs obtained from horse (h), which
have to be considered the gold standard for AA
treatment. Of note, US and Japanese investi-
gators  utilized  hATG  (ATGAM®,  Upjohn;  40
mg/kg/day for 4 days),24,25 which is different
from  the  hATG  preparation  used  in  Europe
(Lymphoglobuline®,  Genzyme;  15  mg/kg/day
for 5 days).20,26 Even if a formal head-to-head
comparison has been never conducted, both h-
ATG  preparations  resulted  in  response  rates
ranging  between  50%  and  70%;20,24-26 thus,
they are considered equivalent as standard IST
for AA. However, since 2008 Lymphoglobuline
is no longer available in Europe, and physi-
cians were forced to utilize other ATG prepara-
tions. Alternative polyclonal ATGs may be ob-
tained  from  rabbits  (r);  two  rATGs  are  cur-
rently available (Thymoglobuline®, Genzyme;
ATG-Fresenius®) but to date the clinical re-
sults with these agents are less robust for the
lack of large randomized trials. Thymoglobu-
line has been utilized in AA patients, and both
retrospective data and prospective series have
demonstrated a substantial efficacy. In most
cases, rATG was used as second-line IST (after
initial hATG) to prevent side effects due to pos-
sible sensitization to horse proteins, resulting
in response rates up to 68% (in relapsed pa-
tients).33,34 As a front-line therapy, the experi-
ence with Thymoglobuline is quite limited; the
only prospective trial is currently ongoing at
NIH, where investigators are comparing head-
to-head  h-ATG  (ATGAM)  and  r-ATG  (Thy-
moglobuline), both arms with CyA, as first line
treatment for AA patients (NCT00260689). The
recruitment  is  now  closed  (60  patients  per
arm),  and  preliminary  data  were  just  pre-
sented at the 2010 ASH meeting;58 very sur-
prisingly, r-ATG was markedly inferior to h-ATG
in terms of response rate (33% vs 62% and 35%
vs 68% at 3 and 6 months, respectively). Of
note,  lymphocyte  depletion  after  r-ATG  was
markedly  longer-lasting  in  comparison  to  h-
ATG, raising the question that lymphocyte de-
pletion may be not sufficient to achieve hema-
tological remission in AA patients. Based on
this  data,  one  could  hypothesize  that  addi-
tional  immune  or  non-immune  mechanisms
may be involved in the pathophysiology of AA,
and  that  h-ATG  may  target  them  more  effi-
ciently than r-ATG. For instance, regardless the
antibodies resulting in T cell depletion, h-ATG
might  contain  antibodies  targeting  immune
cytokines involved in the inhibition or in the
damage of hematopoietic stem cells. The NIH
data were in agreement with a retrospective
study from Brazil,59 which showed a 34.5% re-
sponse rate with Thymoglobuline in compar-
ison to the 59.5% achieved with Lymphoglobu-
line (patients were 42 and 29, respectively).
However, other retrospective experiences are
in contrast with the results of this randomized
study:  investigators  at  the  Cleveland  Clinic
treated 22 naïve AA patient with Thymoglobu-
line, showing a response rate of 50% and 54%
at 6 and 12 months, respectively; these results
were comparable to the historical control of 67
AA  patients  who  have  received  initial  treat-
ment with ATGAM (59% response rate at 6 and
12  months).60 A  similar  retrospective  study
was conducted by the Spanish group,61 which
showed that 75 AA patients receiving front-line
treatment with Thymoglobuline (2.5 mg/kg for
5 days) had a response rate of 45%, which was
comparable to the 49% of the 35 patients who
have  received  Lymphoglobuline.  Additional
studies  are  currently  ongoing  to  investigate
the efficacy of Thymoglobuline: the EBMT is
retrieving its retrospective registry to assess
the  actual  response  rate.  In  addition,  the
EBMT is running a pilot study (NCT00471848)
to investigate whether 2.5 mg/kg/day of Thy-
moglobuline (for 5 days) may be equivalent to
the  most  utilized  dose  (3.75  mg/kg/day).  In-
deed, based on these data, at the moment h-
ATG + CyA seems the safest treatment for AA
patients; Thymoglobuline, which have in any
case a substantial efficacy, should be recom-
mended  only  if  h-ATGs  are  not  available,  or
within  prospective  trials.  Finally,  ATG-Frese-
nius should not be used as IST for AA patients,
given that its use is limited to anecdotic and
disappointing experiences.62
Conclusions
To date, ATG + CyA remains the standard
IST for AA patients. All the attempts to improve
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the results obtained with this regimen have
been unfruitful. Unexpectedly, recent observa-
tion have confounded rather than clarified our
knowledge of IST in AA; in fact, the dogma that
different ATG preparations may be equally ef-
fective has been unexpectedly debunked. The
fact that hematological response does not cor-
relate with lymphocyte depletion also suggest
that h-ATG may work through unknown mech-
anisms of actions, even other than immune,
leading to a possible dispute of AA pathophysi-
ology itself. Even if these data have to be con-
firmed, at the moment h-ATG seems the best
standard of care for AA patients; this repre-
sents a urgent challenge for those Countries
(i.e., Europe) where h-ATG is no longer avail-
able. At the moment, it is not clear whether
novel IS agents or strategies may be useful to
improve the results of current IST; the design
of  large,  co-operative  prospective  studies
seems the only way to unravel the open issues
in IS for the treatment of AA.
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